News - Novartis, Incyte

Filter

Current filters:

NovartisIncyte

Popular Filters

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

Ph III study for Jakavi meets endpoint in patients with polycythemia vera

07-03-2014

Swiss pharma major Novartis today announced positive results from a pivotal Phase III trial of Jakavi…

IncyteJakaviNovartisOncologyPharmaceuticalRare diseasesRegulationResearch

Herve Hoppenot quits Novartis to join Incyte

Herve Hoppenot quits Novartis to join Incyte

13-01-2014

Swiss drug major Novartis said on Sunday (January 12), that Herve Hoppenot, president of Novartis Oncology,…

BoardroomIncyteManagementNovartisPharmaceutical

Novartis/Incyte's Jakafi will be greatest growth driver in myelofibrosis market

31-01-2013

Through 2021, the continued uptake of Novartis (NOVN: VX)/Incyte's (Nasdaq: INCY) recently launched JAK-2…

BiotechnologyCYT387EuropeGilead SciencesIncyteJakafiMarkets & MarketingNorth AmericaNovartisOncologyPharmaceuticalYM Biosciences

First myelofibrosis drug, Novartis' Jakavi, approved in Europe

29-08-2012

Swiss drug major Novartis (NOVN: VX) received approval yesterday from the European Commission for Jakavi…

EuropeIncyteJakafiJakaviNovartisOncologyPharmaceuticalRare diseasesRegulation

US FDA grants priority review as it accepts Incyte ruxolitinib NDA for myelofibrosis

04-08-2011

The US Food and Drug Administration has accepted for filing the New Drug Application (NDA) for drug developer…

IncyteNorth AmericaNovartisOncologyPharmaceuticalRegulationruxolitinib

Back to top